Relypsa For ED Acute Hyperkalemia Control & Reduction (REDUCE)

Status Completed

Clinical Trial Summary

The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.

Clinical Trial Description

This is an open label pilot study. Thirty patients with ESRD who qualify for emergent dialysis on the basis of serum potassium greater than 6mEq/L will be randomly assigned, using a random number generator in blocks of sixes, to standard-of-care (standard care) or patiromer group. Patients in the patiromer group will be given a single dose of 25.2g of patiromer in addition to standard-of-care treatment after randomization. Standard-of-care is defined as intervention or care provided by clinical provider according to individual practice pattern or hospital protocol. Each group of 15 patients will be observed with telemetry monitoring for 10 hours or till hemodialysis units become available for treatment (whichever comes first). Blood draws and electrocardiograms (ECGs) will be performed at enrollment and at 1, 2, 4, 6, 8 and 10hrs thereafter. Serum will be analyzed for basic metabolic panel and magnesium. Medications, including potassium lowering agents, administered during this period will be documented.

1. Informed consent will be obtained. 2. Subject will be randomized. 3. A. Randomized to Standard of Care (SOC): data will be collected on SOC treatment. 3. B. Randomized to patiromer group: subjects will receive a single dose of 25.2g of patiromer. SOC data will be collected. 4. all subjects will have blood drawn and ECGs (1 12 lead ECG and 1 Lead I Rhythm strip) done at baseline, 1, 2, 4, 6, 8 and 10 hours. Blood will be analyzed for basic metabolic panel and magnesium. 5. CRF completion-SOC data will be recorded in addition to current medications. 6. After subjects have received hemodialysis or reach the 10 hour study period, whichever comes first, the subject will be completed on the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02933450
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	August 2016
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT02922361` - Spending and Outcomes for Complex Medicare Advantage Patients
Completed	`NCT02235571` - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients	N/A
Completed	`NCT01930396` - Use of Tinzaparin for Anticoagulation in Hemodialysis	Phase 4
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Completed	`NCT01922843` - A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis	Phase 2
Not yet recruiting	`NCT01674660` - Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients	N/A
Completed	`NCT01209403` - Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients	Phase 4
Not yet recruiting	`NCT01157260` - The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT00753116` - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension	Phase 1
Recruiting	`NCT00532688` - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure	Phase 2/Phase 3
Completed	`NCT00534144` - Comparison Between Effects of Two Iron Preparations on Protein in the Urine	Phase 1
Completed	`NCT00528788` - How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis	Phase 4
Completed	`NCT00382044` - Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients	N/A
Completed	`NCT00226902` - Vascular Reactivity in Kidney Disease Patients	N/A
Recruiting	`NCT00235287` - Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease	Phase 4
Completed	`NCT00224081` - DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)	Phase 4
Completed	`NCT00071214` - Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis	Phase 3
Completed	`NCT00049907` - Cardiac and Renal Disease Study (CARDS)	N/A
Completed	`NCT00006297` - Risk Factors for CV Disease in a Dialysis Cohort	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms